NCT06073691: IEPD

Interoceptive Exposure in Panic Disorder

Completed NA Last updated 10 October 2023

What this trial tests

NA trial testing Exercise intervention in Panic Attacks and Disorders in 72 participants. Completed in 1 December 2016.

Timeline

1 July 2015

Primary endpoint
1 July 2016

1 December 2016

Quick facts

Lead sponsor	University of Sao Paulo General Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	treatment
Enrollment	72
Start date	1 July 2015
Primary completion	1 July 2016
Estimated completion	1 December 2016

Drugs / interventions tested

• Exercise intervention
• Placebo

Conditions studied

• Panic Attacks and Disorders — all drugs for Panic Attacks and Disorders →

Sponsor

University of Sao Paulo General Hospital

Who can join

18 and older, any sex, with Panic Attacks and Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to test action exercises in the treatment of people with a diagnosis of Panic disorders with or without agoraphobia.

The main question it aims to answer is:

To investigate the feasibility and effectiveness of a Panic Disorder (PD) treatment protocol based on anaerobic exercise as an interoceptive exposure therapy.

Participants will The participants were randomly allocated to a 12-week program of either Intermittent Anaerobic Exercise.

Researchers will compare two groups, one with treatment through an intermittent aerobic exercise (IAE) protocol and the other group with treatment via a muscle relaxation protocol (RT), to see if there is feasibility and efficacy of a Panic Disorder treatment protocol based on anaerobic exercise as exposure therapy, compared to a relaxation activity.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Brief intermittent intense exercise as interoceptive exposure for panic disorder: a randomized controlled clinical trial.
   Muotri RW, Luciano AC, Garrudo Guirado A, Lotufo Neto F, et al · · 2025 · PMID 41737725 · DOI 10.3389/fpsyt.2025.1739639